Nigeria
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 174 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 160 (68–270) 94 (39–156)
Mortality (HIV+TB only) 85 (47–140) 49 (27–78)
Prevalence  (includes HIV+TB) 570 (430–730) 326 (246–418)
Incidence  (includes HIV+TB) 590 (340–880) 338 (194–506)
Incidence (HIV+TB only) 140 (81–220) 81 (47–124)
Case detection, all forms (%) 16 (11–28)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.9 (2.1–4) 14 (10–19)
MDR-TB cases among notified pulmonary
TB cases
2 500 (1 800–3 500) 1 200 (860–1 600)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 52 811   2 828
Pulmonary, clinically diagnosed 33 873    
Extrapulmonary 5 313    
       
Total new and relapse 94 825    
Previously treated, excluding relapses 5 576    
Total cases notified 100 401    
Among 100 401 new and relapse cases:
5 776 (6%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB     10 410
Laboratory-confirmed RR-/MDR-TB cases     554
Patients started on MDR-TB treatment     426
TB/HIV 2013 Number (%)
TB patients with known HIV status 88 317 (88)
HIV-positive TB patients 19 423 (22)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 16 948 (87)
HIV-positive TB patients on antiretroviral therapy (ART) 12 923 (67)
HIV-positive people screened for TB 435 216  
HIV-positive people provided with IPT 7 973  
Treatment success rate (%)
New cases registered in 2012 86
Previously treated cases registered in 2012 83
HIV-positive TB cases, all types, registered in 2012 79
RR-/MDR-TB cases started on second-line treatment in 2011 63
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.1
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 49
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 139
% Funded domestically 9%
% Funded internationally 38%
% Unfunded 53%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-28 Data: www.who.int/tb/data